Eli Lilly and Company / LLY

Equity | Generated Nov 10, 2026 11:31 PM EST

Current price	Daily move	Bid / Ask	Previous close
$1,420.50	+8.55 +0.61%	$1,419.43/$1,423.65	$1,411.95

Market	NYSE
Industry	Pharmaceuticals
Market data as of	Nov 10, 2026 11:31 PM EST

JW Intelligence Report

Complete | 3 of 3 sections | Nov 10, 2026 6:50 PM EST

JW Rank	Rank label	Confidence	IV percentile
71.0 / 100	Constructive	high	28 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,415.00	$1,485.00	$1,365.00	61 / 100

Options stance	bullish
Tail-risk safety	44 / 100
JW Rank data coverage / as of	100.0% | Nov 10, 2026 6:50 PM EST

Key insight

LLY Option Market Implies Continued Upside Potential

Market read

The market for LLY options suggests continued bullish sentiment. The stock is trading near its 52-week high, and implied volatility is elevated, reflecting investor expectations of significant price movement in the coming weeks. Strong technical indicators, including a positive trend and momentum, support this view. Recent earnings beat expectations and raised guidance, further fueling optimism. However, the stock's valuation is considered rich, and potential risks include competition, manufacturing scale, and safety concerns surrounding GLP-1 drugs.

Strategy context

The market appears to be pricing in continued growth for LLY, driven by strong demand for its diabetes and obesity treatments. However, the stock's valuation is high, and investors may be cautious about further upside.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Nov 10, 2026 2:15 PM EST**

Short-term scenario

Mildly bullish bias over 1-3 weeks on momentum and recent positive catalysts, favoring a dip entry rather than chasing near highs. Uncertainty is high due to proximity to the 52-week high, elevated RSI, and possible profit-taking or broader market swings.

Three-month outlook

Constructive base case supported by continued incretin volume growth, oral Foundayo expansion potential (including possible OSA indication), retatrutide and other pipeline progress, and the raised 2026 outlook. Most analysts remain Buy-rated. Offsetting risks include rich multiples, realized-price declines, competition, manufacturing scale, and any further safety scrutiny of the GLP-1 class. Uncertainty is material: path depends on whether volume surprises continue to outpace multiple compression; modest upside with elevated volatility is a reasonable central expectation rather than a high-conviction forecast.

Market sentiment

Recent keyword posts are dominated by low-engagement spam accounts uniformly advising against buying LLY. More substantive commentary from prior weeks is predominantly bullish, citing accumulation, obesity-market scale, pipeline optionality, and positive reactions to Foundayo sleep-apnea data and the earnings beat. Overall serious investor tone appears constructive on fundamentals but social feeds are noisy. Uncertainty: X sentiment is unreliable as a signal given promotional content and does not reflect institutional positioning.

Supporting evidence


LLY options exhibit elevated implied volatility (32.7%), suggesting anticipation of significant price swings. | The term structure of LLY options shows a slight negative slope, indicating that near-term options are more expensive than longer-dated options. | Technical indicators point to a strong bullish trend with the stock trading above both its 50 and 200 day moving averages. | Recent earnings exceeded expectations, driving positive sentiment and raising guidance for the year.

Risk watch

Competition from other pharmaceutical companies developing similar drugs could impact LLY's market share. | Manufacturing capacity constraints could limit LLY's ability to meet growing demand for its products.

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Above MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | neutral | MACD decelerating**
Trend signal	**STRONG BULL**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**70.94 / 69.82 / 67.88**
RSI velocity	**2.14**
MACD line / signal / histogram	**56.04 / - / 50.47**
MACD acceleration	**-0.16**
Stochastic K / D	**72.57 / 66.42**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Accumulation bias**
Institutional flow	**6.59**
20-day MVWAP	**$1,344.02**
Price vs 20-day MVWAP	**+5.69%**
Daily reference VWAP	**$1,423.72**
Price vs daily reference	**-0.23%**
Volume	**1.48M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**11.16**
20-day / 200-day SMA	**$1,326.71 / $1,103.22**
Bollinger range	**$1,182.22 - $1,471.20**
Bollinger position	**0.865**

Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
27 / 100	31 / 100	98.64	150.34

Market regime	**Calm**
Tail-risk regime	**HIGH TAIL RISK**
Term structure	**flat**
Term slope	**-1.81 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 10, 2026 2:51 PM EST**
Options data quality	**Coverage 100.0%**

Option term structure

ATM implied-volatility curve by days to expiration



Downward-sloping ATM volatility term structure


EXPIRATION	DTE	ATM IV	STATE
2026-11-13	3	32.7%	-
2026-11-20	10	31.6%	-
2026-11-27	17	30.9%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference


Short $1,400.00 | Long $1,395.00 | Width $5.00 | Net credit $1.18



Max profit $118.00 | Max loss -$382.00 | Break-even $1,398.82 | Per contract at expiry

Bear Call Spread reference

Short $1,460.00 | Long $1,465.00 | Width $5.00 | Net credit $1.07



Max profit $107.00 | Max loss -$393.00 | Break-even $1,461.07 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**moderate**
Event IV premium	**1.03**
VIX	**19.77**
VVIX	**98.64**
SKEW index	**150.34**
Observation confidence	**high**
Option quote quality	**reliable**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts observed	**112**
Contracts with quotes	**112**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The market for LLY options suggests continued bullish sentiment. The stock is trading near its 52-week high, and implied volatility is elevated, reflecting investor expectations of significant price movement in the coming weeks. Strong technical indicators, including a positive trend and momentum, support this view. Recent earnings beat expectations and raised guidance, further fueling optimism. However, the stock's valuation is considered rich, and potential risks include competition, manufacturing scale, and safety concerns surrounding GLP-1 drugs.

Options context

LLY Option Market Implies Continued Upside Potential

Wheel context

The market appears to be pricing in continued growth for LLY, driven by strong demand for its diabetes and obesity treatments. However, the stock's valuation is high, and investors may be cautious about further upside.

Observed evidence

LLY options exhibit elevated implied volatility (32.7%), suggesting anticipation of significant price swings. | The term structure of LLY options shows a slight negative slope, indicating that near-term options are more expensive than longer-dated options. | Technical indicators point to a strong bullish trend with the stock trading above both its 50 and 200 day moving averages. | Recent earnings exceeded expectations, driving positive sentiment and raising guidance for the year.

Principal risks to monitor

Competition from other pharmaceutical companies developing similar drugs could impact LLY's market share. | Manufacturing capacity constraints could limit LLY's ability to meet growing demand for its products.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.33T	**46.19**
ROE	Revenue growth
83.7%	**31.7%**
EPS growth	Operating margin
49.3%	**40.3%**
Net profit margin	Gross margin
31.9%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.39**

52-week range

$850.51 - $1,453.00

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
940.75M	**44.4%**
Book value per share	Revenue per share
$42.79	**$96.78**

Website	**lilly.com**

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Nov 4, 2026 3:45 PM EST

Covered Call | 2026-11-06

At signal $1,422.74 | Current $1,420.50

SHORT **Option $1,425.00 B $14.30 / A $14.95**

Conservative | CR $14.63

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$47.96**
ATR as % of price	**3.4%**
Volatility environment	**medium**
Current IV	**32.4%**
IV rank	**25 / 100**
IV percentile	**28 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Nov 10, 2026 6:31 PM EST**

Technical health and risk radar

Derived indicator health and event context

Overall health	**75 / 100**
Trend health	**92 / 100**
Momentum health	**73 / 100**
Volatility health	**60 / 100**
Structure health	**63 / 100**
Earnings risk / date	**unknown | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**medium**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,326.71 / $1,224.51 / $1,103.22**
EMA (9 / 21)	**$1,383.77 / $1,330.22**
Bollinger upper / middle / lower	**$1,471.20 / $1,326.71 / $1,182.22**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.865**
True high / low	**$1,438.88 / $1,400.00**
5-day true high / low	**$1,453.00 / $1,333.22**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	11.164	**-**
SMA50	4.605	**-**
MVWAP20	6.592	**-**
MACD	-0.162	**-**
RSI	2.136	**-**
Volume	-606315.000	**-**
ATR	0.119	**-**
T1	-	**54.10 / 1336.23 / 1419.67 / 1354.00**
T2	-	**52.92 / 1329.82 / 1377.28 / 1333.22**
T3	-	**56.53 / 1324.24 / 1453.00 / 1364.73**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,432.00**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 10, 2026 2:51 PM EST**
Options data coverage	**100.0%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-11-13 | 3 DTE**
Front at-the-money IV	**32.7%**
25-delta skew	**2.56**
Put / Call 25-delta	**$1,400.00 Delta -0.243 / $1,460.00 Delta 0.254**
Median option bid/ask spread	**8.2%**
Bid/ask spread	**-**
Contracts observed / quoted	**112 / 112**

Price context

Last Price: 1,432.00 | Bid: 1,431.67 | Ask: 1,432.32 | Previous Close: 1,411.96 | Change: 20.04 | Daily change: 1.42% | Update Time: 2026-11-10T14:51:44.165775-05:00 | Latest History Date: 2026-11-10 | Latest History Price: 1,432.71

Historical context

Trading-day sample: 60 sessions | First Date: 2026-08-18 | Latest Date: 2026-11-10 | Latest Price: 1,432.71 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 32.70% | Iv Rank: 26.77 | Iv Percentile: 30.68 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Nov 10, 2026 11:31 PM EST. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**